Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups.

Nicotine metabolism influences smoking behavior and differences in metabolism probably contribute to ethnic variability in lung cancer risk. We report here on the proportion of nicotine metabolism by cytochrome P450 2A6-catalyzed C-oxidation, UDP-glucuronosyl transferase 2B10 (UGT2B10)-catalyzed N-glucuronidation and flavin monooxygenase 3-catalyzed N-oxidation in five ethnic/racial groups and the role of UGT2B10 genotype on the metabolic patterns observed. Nicotine and its metabolites were quantified in urine from African American (AA, n = 364), Native Hawaiian (NH, n = 311), White (n = 437), Latino (LA, n = 453) and Japanese American (JA, n = 674) smokers. Total nicotine equivalents, the sum of nicotine and six metabolites, and nicotine metabolism phenotypes were calculated. The relationship of UGT2B10 genotype to nicotine metabolic pathways was determined for each group; geometric means were computed and adjusted for age, sex, creatinine, and body mass index. Nicotine metabolism patterns were unique across the groups, C-oxidation was lowest in JA and NH (P < 0.0001), and N-glucuronidation lowest in AA (P < 0.0001). There was no difference in C-oxidation among Whites and AA and LA. Nicotine and cotinine glucuronide ratios were 2- and 3-fold lower in AA compared with Whites. Two UGT variants, a missense mutation (Asp67Tyr, rs61750900) and a splice variant (rs116294140) accounted for 33% of the variation in glucuronidation. In AA, the splice variant accounted for the majority of the reduced nicotine glucuronidation. UGT2B10 variant allele carriers had increased levels of C-oxidation (P = 0.0099). Our data indicate that the relative importance of nicotine metabolic pathways varies by ethnicity, and all pathways should be considered when characterizing the role of nicotine metabolism on smoking behavior and cancer risk.

[1]  E. Szabo,et al.  Fifty Years of Tobacco Carcinogenesis Research: From Mechanisms to Early Detection and Prevention of Lung Cancer , 2014, Cancer Prevention Research.

[2]  M. Finel,et al.  Human UDP-Glucuronosyltransferase (UGT) 2B10 in Drug N-Glucuronidation: Substrate Screening and Comparison with UGT1A3 and UGT1A4 , 2013, Drug Metabolism and Disposition.

[3]  L. Bierut,et al.  Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption , 2013, Pharmacogenetics and genomics.

[4]  D. Hatsukami,et al.  The Ability of Plasma Cotinine to Predict Nicotine and Carcinogen Exposure is Altered by Differences in CYP2A6: the Influence of Genetics, Race, and Sex , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[5]  S. Murphy,et al.  CYP2A6- and CYP2A13-Catalyzed Metabolism of the Nicotine Δ5′(1′)Iminium Ion , 2012, Journal of Pharmacology and Experimental Therapeutics.

[6]  Y. Okada,et al.  Haplotypes with Copy Number and Single Nucleotide Polymorphisms in CYP2A6 Locus Are Associated with Smoking Quantity in a Japanese Population , 2012, PloS one.

[7]  L. Bierut,et al.  Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. , 2012, Human molecular genetics.

[8]  P. Lazarus,et al.  Glucuronidation of trans-3′-hydroxycotinine by UGT2B17 and UGT2B10 , 2012, Pharmacogenetics and genomics.

[9]  O. Delaneau,et al.  A linear complexity phasing method for thousands of genomes , 2011, Nature Methods.

[10]  M. Spitz,et al.  Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. , 2011, Journal of the National Cancer Institute.

[11]  Q. Liang,et al.  Is 24h nicotine equivalents a surrogate for smoke exposure based on its relationship with other biomarkers of exposure? , 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[12]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[13]  A. Berg,et al.  Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms. , 2010, Cancer research.

[14]  D. Hatsukami,et al.  UGT2B10 Genotype Influences Nicotine Glucuronidation, Oxidation, and Consumption , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[15]  D. Hatsukami,et al.  Nicotine Metabolism in African Americans and European Americans: Variation in Glucuronidation by Ethnicity and UGT2B10 Haplotype , 2010, Journal of Pharmacology and Experimental Therapeutics.

[16]  L. Le Marchand,et al.  Exposure to the carcinogen 4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanone (NNK) in smokers from 3 populations with different risks of lung cancer , 2009, International journal of cancer.

[17]  S. Feng,et al.  Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers. , 2009, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[18]  P. Donnelly,et al.  A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies , 2009, PLoS genetics.

[19]  Jiantong Wang,et al.  Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. , 2009, American journal of epidemiology.

[20]  L. Le Marchand,et al.  Nicotine Metabolism in Three Ethnic/Racial Groups with Different Risks of Lung Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[21]  R. Dellinger,et al.  Glucuronidation of Tobacco-Specific Nitrosamines by UGT2B10 , 2008, Drug Metabolism and Disposition.

[22]  R. Dellinger,et al.  Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines , 2008, Pharmacogenetics and genomics.

[23]  R. Dellinger,et al.  Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism. , 2007, Cancer research.

[24]  M. Finel,et al.  Nicotine Glucuronidation and the Human UDP-Glucuronosyltransferase UGT2B10 , 2007, Molecular Pharmacology.

[25]  G. Scherer,et al.  Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany. , 2007, Regulatory toxicology and pharmacology : RTP.

[26]  Christina N. Lessov-Schlaggar,et al.  CYP2A6 genotype and the metabolism and disposition kinetics of nicotine , 2006, Clinical pharmacology and therapeutics.

[27]  S. Murphy,et al.  Identification of N-(hydroxymethyl) norcotinine as a major product of cytochrome P450 2A6, but not cytochrome P450 2A13-catalyzed cotinine metabolism. , 2005, Chemical research in toxicology.

[28]  S. Murphy,et al.  NICOTINE 5′-OXIDATION AND METHYL OXIDATION BY P450 2A ENZYMES , 2005, Drug Metabolism and Disposition.

[29]  Neal L. Benowitz,et al.  Metabolism and Disposition Kinetics of Nicotine , 2005, Pharmacological Reviews.

[30]  S. Hecht,et al.  Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. , 2005, Chemical research in toxicology.

[31]  J. Yokota,et al.  Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. , 2004, Carcinogenesis.

[32]  D. Hatsukami,et al.  A comparison of urinary biomarkers of tobacco and carcinogen exposure in smokers. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[33]  S. Murphy,et al.  N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP-glucuronosyltransferases. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[34]  D O Stram,et al.  A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. , 2000, American journal of epidemiology.

[35]  E. Perez-stable,et al.  Ethnic differences in N-glucuronidation of nicotine and cotinine. , 1999, The Journal of pharmacology and experimental therapeutics.

[36]  E. Perez-stable,et al.  Nicotine metabolism and intake in black and white smokers. , 1998, JAMA.

[37]  G. Giovino,et al.  Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991. , 1998, JAMA.

[38]  C. S. Yang,et al.  Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine alpha-hydroxylation by human liver microsomes. , 1997, Carcinogenesis.

[39]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[40]  Malcolm C Pike,et al.  Ethnic and racial differences in the smoking-related risk of lung cancer. , 2006, The New England journal of medicine.

[41]  S. Hecht,et al.  Cytochrome P450 2A-catalyzed metabolic activation of structurally similar carcinogenic nitrosamines: N'-nitrosonornicotine enantiomers, N-nitrosopiperidine, and N-nitrosopyrrolidine. , 2005, Chemical research in toxicology.

[42]  G. Giovino,et al.  Racial and Ethnic Differences in Serum Cotinine Levels of Cigarette Smokers , 1998 .

[43]  C. S. Yang,et al.  Evidence for cytochrome P 450 2 A 6 and 3 A 4 as major catalysts for N 9-nitrosonornicotine α-hydroxylation by human liver microsomes , 1997 .

[44]  D. Jacobs,et al.  Racial differences in serum cotinine levels among smokers in the Coronary Artery Risk Development in (Young) Adults study. , 1990, American journal of public health.

[45]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[46]  J. Palca.  Nicotine addiction , 1988, Nature.